AeroFact
Phase 3- Indications
- Neonatal Respiratory Distress Syndrome
Company intelligence / Profile preview
Nuance Pharma
Shanghai, Shanghai, China
- Ownership
- Private
- Employees
- ~500
- Development stage
- Commercial
01
Overview
Nuance Pharma has both commercial products and late-stage clinical pipeline assets. Their product Ohtuvayre (ensifentrine) was approved by the US FDA in 2024 for COPD maintenance treatment and in Macau SAR, China in 2025. They have completed dosing of the first patient in Ensifentrine China phase 3 trial for COPD in 2023.
- Therapeutic areas
- PulmonologyImmunologyOtherHematologyNeurology
- Modalities
- Small molecule drugsBiologicsDrug-device combinations
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Verona PharmaAerogen PharmaAltamira TherapeuticsNeumentum
Beyond the preview
Go deeper on Nuance Pharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Nuance Pharma.